Title: RIP140 Regulation of Glucose Transport
Patent Number: 7,691,823
Filed: March 7, 2005
Lead Inventor: Michael Czech, University of Massachusetts (RXi Pharmaceuticals)
"Inhibition of RIP140 increases glucose transport," the patent's abstract states. "Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport, treating obesity, increasing metabolism, and increasing brown fat."
The patent specifically claims the use of an siRNA to inhibit RIP140.
Title: Compositions and Methods for Inhibiting Expression of a Gene from the JC Virus
Patent Number: 7,691,824
Filed: April 27, 2007
Lead Inventor: Pamela Tan, Alnylam Pharmaceuticals
"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the JC virus, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC virus," the patent's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC virus in a cell."
Title: In Vivo Production of Small Interfering RNAs that Mediate Gene Silencing
Patent Number: 7,691,995
Filed: July 12, 2002
Lead Inventor: Phillip Zamore, University of Massachusetts
"The invention provides engineered RNA precursors that, when expressed in a cell, are processed by the cell to produce targeted small interfering RNAs that selectively silence targeted genes using the cell's own RNA interference pathway," according to the patent's abstract. "By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells."
Title: Functional and Hyperfunctional siRNA
Patent Number: 7,691,997
Filed: April 7, 2005
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."
Title: siRNA Targeting Nucleoporin 62kDa
Patent Number: 7,691,998
Filed: June 9, 2008
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for Nup62."
Title: RNA Interference-Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid
Patent Number: 7,691,999
Filed: July 16, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
"This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid molecules," according to the patent's abstract. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of NOGO and/or NOGO receptor genes, such as NOGO-A, NOGO-B, NOGO-C, NOGO-66 receptor, NI-35, NI-220, NI-250, myelin-associated glycoprotein, tenascin-R, and NG-2."